Evaluation of Serum Symmetric Dimethylarginine Concentration as a Marker for Masked Chronic Kidney Disease in Cats

M E Peterson1,2, F V Varela1, M Rishniw2,3

  • 1Animal Endocrine Clinic , New York, NY.

Insights

Serum symmetric dimethylarginine (SDMA) can help predict azotemic chronic kidney disease (CKD) in hyperthyroid cats. While highly specific, SDMA has low sensitivity for identifying masked azotemia before treatment.

Area of Science:

  • Veterinary Medicine
  • Nephrology
  • Endocrinology

Background:

  • Hyperthyroidism can mask chronic kidney disease (CKD) in cats by altering kidney function markers.
  • Current diagnostic methods lack reliability in predicting azotemic CKD in hyperthyroid cats post-treatment.

Purpose of the Study:

  • To evaluate serum symmetric dimethylarginine (SDMA) as a predictive marker for masked azotemia in hyperthyroid cats.
  • To assess the diagnostic accuracy of SDMA in identifying cats with pre-azotemic CKD.

Main Methods:

  • A prospective study involving 262 hyperthyroid cats and 206 healthy controls.
  • Measurement of creatinine, urea nitrogen, SDMA, T4, and TSH before and after radioiodine (131I) treatment.
  • Azotemia classification based on post-treatment creatinine levels (>2.1 mg/dL).

Main Results:

  • 16% of hyperthyroid cats developed azotemia post-treatment.
  • Pre-treatment SDMA was elevated in 14 of the 42 cats that became azotemic.
  • SDMA demonstrated 33.3% sensitivity and 97.7% specificity for predicting pre-azotemic CKD.

Conclusions:

  • Elevated serum SDMA in hyperthyroid cats can indicate a risk of developing azotemia after treatment.
  • SDMA offers high specificity but limited sensitivity for detecting masked azotemic CKD in this population.
Abstract

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
780
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
700
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
488
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
416
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance01:25

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance...
233
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
241